- Home
- ADAMM vs OGN Comparison
ADAMM vs OGN Comparison
Compare ADAMM & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAMM
- OGN
- Stock Information
- Founded
- ADAMM N/A
- OGN 1923
- Country
- ADAMM United States
- OGN United States
- Employees
- ADAMM N/A
- OGN N/A
- Industry
- ADAMM Real Estate Investment Trusts
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- ADAMM Real Estate
- OGN Health Care
- Exchange
- ADAMM Nasdaq
- OGN Nasdaq
- Market Cap
- ADAMM 2.3B
- OGN 2.7B
- IPO Year
- ADAMM N/A
- OGN N/A
- Fundamental
- Price
- ADAMM N/A
- OGN $10.27
- Analyst Decision
- ADAMM
- OGN Hold
- Analyst Count
- ADAMM 0
- OGN 4
- Target Price
- ADAMM N/A
- OGN $18.00
- AVG Volume (30 Days)
- ADAMM N/A
- OGN 3.6M
- Earning Date
- ADAMM N/A
- OGN 10-30-2025
- Dividend Yield
- ADAMM N/A
- OGN 0.78%
- EPS Growth
- ADAMM N/A
- OGN N/A
- EPS
- ADAMM N/A
- OGN 2.69
- Revenue
- ADAMM N/A
- OGN $6,281,000,000.00
- Revenue This Year
- ADAMM N/A
- OGN N/A
- Revenue Next Year
- ADAMM N/A
- OGN $1.36
- P/E Ratio
- ADAMM N/A
- OGN $3.82
- Revenue Growth
- ADAMM N/A
- OGN N/A
- 52 Week Low
- ADAMM N/A
- OGN $8.01
- 52 Week High
- ADAMM N/A
- OGN $21.06
- Technical
- Relative Strength Index (RSI)
- ADAMM N/A
- OGN 62.24
- Support Level
- ADAMM N/A
- OGN $8.95
- Resistance Level
- ADAMM N/A
- OGN $10.58
- Average True Range (ATR)
- ADAMM 0.00
- OGN 0.35
- MACD
- ADAMM 0.00
- OGN 0.14
- Stochastic Oscillator
- ADAMM 0.00
- OGN 80.92
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.